![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
STARTVerso4 PHASE III TRIAL OF FALDAPREVIR PLUS PEGYLATED INTERFERON α-2a AND RIBAVIRIN IN PATIENTS WITH HIV AND HCV GENOTYPE-1 CO-INFECTION
|
|
|
Download the PDF here
Reported by Jules Levin
AASLD 2013 Nov 1-4 Wash DC
JK Rockstroh1, M Nelson2, V Soriano3, K Arasteh4, J Guardiola5, S Bhagani6, J Mallolas7, C Tural8, M Puoti9, P Ingiliz10, M Battegay11, MK Jain12, M Nuñez13, K Marks14, J Kort15, JO Stern15, R Vinisko15, M Manero16, D Dieterich17, on behalf of the STARTVerso4 Study Group
1University of Bonn, Bonn, Germany; 2Chelsea and Westminster Hospital, London, UK; 3Hospital Carlos III, Madrid, Spain; 4EPIMED, Vivantes Auguste-Viktoria Hospital, Berlin, Germany; 5Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; 6Royal Free Hospital, London, UK; 7Hospital Clínic, Barcelona, Spain; 8Hospital Universitari Germans Trias i Pujol, Barcelona, Spain; 9AO Ospedale Niguarda Ca Granda, Milan, Italy; 10Medizinisches Infektiologiezentrum Berlin (MIB), Berlin, Germany; 11Division of Infectious Diseases and Hospital Epidemiology, Basel, Switzerland; 12UT Southwestern Medical Center, Dallas, TX, USA; 13Wake Forest University, Winston-Salem, NC, USA; 14Weill Cornell Medical College, New York, NY, USA; 15Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA; 16Boehringer Ingelheim España S.A., Barcelona, Spain; 17Mount Sinai School of Medicine, New York, NY, USASTART
V
![image002.gif](../images/111013/111013-6/image002.gif)
![image004.gif](../images/111013/111013-6/image004.gif)
![image006.gif](../images/111013/111013-6/image006.gif)
![image008.gif](../images/111013/111013-6/image008.gif)
![image010.gif](../images/111013/111013-6/image010.gif)
![image012.gif](../images/111013/111013-6/image012.gif)
![image014.gif](../images/111013/111013-6/image014.gif)
![image016.gif](../images/111013/111013-6/image016.gif)
![image018.gif](../images/111013/111013-6/image018.gif)
![image020.gif](../images/111013/111013-6/image020.gif)
![image022.gif](../images/111013/111013-6/image022.gif)
![image024.gif](../images/111013/111013-6/image024.gif)
![image026.gif](../images/111013/111013-6/image026.gif)
![image028.gif](../images/111013/111013-6/image028.gif)
![image030.gif](../images/111013/111013-6/image030.gif)
![image032.gif](../images/111013/111013-6/image032.gif)
![image034.gif](../images/111013/111013-6/image034.gif)
![image036.gif](../images/111013/111013-6/image036.gif)
![image038.gif](../images/111013/111013-6/image038.gif)
![image040.gif](../images/111013/111013-6/image040.gif)
![image042.gif](../images/111013/111013-6/image042.gif)
![image044.gif](../images/111013/111013-6/image044.gif)
![image046.gif](../images/111013/111013-6/image046.gif)
![image048.gif](../images/111013/111013-6/image048.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|